(Q37780022)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709660%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

review article

1 reference

title

Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709660%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

5

Ola Landgren

1 reference

PubMed publication ID

23 August 2017

Adam J Waxman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709660%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Michael Kuehl

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709660%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Arun Balakumaran

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709660%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Brendan Weiss

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709660%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Ola Landgren

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709660%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

language of work or name

English

0 references

publication date

1 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709660%20AND%20SRC:MED&resulttype=core&format=json

Clinical Lymphoma, Myeloma & Leukemia

10 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709660%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709660%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709660%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

page(s)

248-257

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709660%20AND%20SRC:MED&resulttype=core&format=json

The potential role of curcumin in patients with monoclonal gammopathy of undefined significance--its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker

10 February 2020

cites work

1 reference

12 December 2020

Clinical and biological significance of RAS mutations in multiple myeloma.

1 reference

12 December 2020

Smoldering multiple myeloma

1 reference

12 December 2020

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

1 reference

12 December 2020

Curcumin (Diferuloylmethane) Inhibits Constitutive and IL-6-Inducible STAT3 Phosphorylation in Human Multiple Myeloma Cells

1 reference

12 December 2020

A new pet for myeloma

1 reference

12 December 2020

Prevalence of monoclonal gammopathy of undetermined significance

1 reference

12 December 2020

Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States

1 reference

12 December 2020

Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades

1 reference

12 December 2020

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

12 December 2020

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

1 reference

12 December 2020

Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors

1 reference

12 December 2020

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

1 reference

12 December 2020

Thalidomide and lenalidomide: Mechanism-based potential drug combinations

1 reference

12 December 2020

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

12 December 2020

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

1 reference

12 December 2020

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

12 December 2020

Genomic abnormalities in monoclonal gammopathy of undetermined significance

1 reference

12 December 2020

Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma

1 reference

12 December 2020

The malignant clone and the bone-marrow environment

1 reference

12 December 2020

Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation

1 reference

12 December 2020

Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma.

1 reference

12 December 2020

1 reference

12 December 2020

Dynamic Contrast-Enhanced Magnetic Resonance Imaging Identifies a Subgroup of Patients with Asymptomatic Monoclonal Plasma Cell Disease and Pathologic Microcirculation

1 reference

12 December 2020

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma

1 reference

12 December 2020

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

1 reference

12 December 2020

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

12 December 2020

Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana

1 reference

12 December 2020

A monoclonal gammopathy precedes multiple myeloma in most patients

1 reference

12 December 2020

Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach.

1 reference

12 December 2020

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

1 reference

12 December 2020

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

1 reference

12 December 2020

Induction of angiogenesis during the transition from hyperplasia to neoplasia

1 reference

12 December 2020

Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors

1 reference

12 December 2020

Smoldering, asymptomatic stage 1, and indolent myeloma

1 reference

12 December 2020

Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease

1 reference

12 December 2020

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

1 reference

12 December 2020

Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study

1 reference

12 December 2020

Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors

1 reference

12 December 2020

Monoclonal gammopathy of undetermined significance

1 reference

12 December 2020

Fracture risk in monoclonal gammopathy of undetermined significance

1 reference

12 December 2020

Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression

1 reference

12 December 2020

Toll-like receptors mediate proliferation and survival of multiple myeloma cells

1 reference

12 December 2020

MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis

1 reference

12 December 2020

The molecular classification of multiple myeloma

1 reference

12 December 2020

Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1.

1 reference

12 December 2020

Inflammation and multiple myeloma: the Toll connection

1 reference

12 December 2020

Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important.

1 reference

12 December 2020

Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma

1 reference

12 December 2020

Immunophenotyping of plasma cells in multiple myeloma.

1 reference

12 December 2020

Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells

1 reference

12 December 2020

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib

1 reference

12 December 2020

p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies

1 reference

12 December 2020

DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance

1 reference

12 December 2020

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

1 reference

12 December 2020

Prevention of progression in monoclonal gammopathy of undetermined significance

1 reference

12 December 2020

Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies

1 reference

12 December 2020

A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

1 reference

12 December 2020

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

12 December 2020

Prognosis of asymptomatic multiple myeloma

1 reference

12 December 2020

Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden

1 reference

12 December 2020

Genetic events in the pathogenesis of multiple myeloma

1 reference

12 December 2020

Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden

1 reference

12 December 2020

Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case

1 reference

12 December 2020

Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma

1 reference

12 December 2020

Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.

1 reference

12 December 2020

Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma

1 reference

12 December 2020

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

12 December 2020

Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells

1 reference

12 December 2020

Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)

1 reference

12 December 2020

Proteasome inhibitors in the treatment of multiple myeloma

1 reference

12 December 2020

Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells

1 reference

12 December 2020

Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis

1 reference

12 December 2020

Mechanism of action of lenalidomide in hematological malignancies

1 reference

12 December 2020

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

1 reference

12 December 2020

Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component

1 reference

12 December 2020

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma

1 reference

12 December 2020

Fracture risk in patients with monoclonal gammopathy of undetermined significance

1 reference

12 December 2020

Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma

1 reference

12 December 2020

Genetics and cytogenetics of multiple myeloma: a workshop report

1 reference

12 December 2020

Smoldering multiple myeloma: natural history and recognition of an evolving type

1 reference

12 December 2020

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

1 reference

12 December 2020

Thalidomide for previously untreated indolent or smoldering multiple myeloma

1 reference

12 December 2020

Functional tumor imaging with dynamic contrast‐enhanced magnetic resonance imaging

1 reference

12 December 2020

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells

1 reference

12 December 2020

Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders

1 reference

12 December 2020

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transpla

1 reference

12 December 2020

MicroRNAs: genomics, biogenesis, mechanism, and function

1 reference

12 December 2020

Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis

1 reference

12 December 2020

MicroRNA signatures in human cancers

1 reference

12 December 2020

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

1 reference

12 December 2020

Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden

1 reference

12 December 2020

Risk of disease progression in asymptomatic multiple myeloma

1 reference

12 December 2020

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

1 reference

12 December 2020

Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis

1 reference

12 December 2020

Identifiers

DOI

10.3816/CLML.2010.N.053

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709660%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709660%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

PubMed publication ID

20709660

1 reference